CX3CL1 Antibody
Code | Size | Price |
---|
PSI-2099-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-2099-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
CX3CL1 Antibody: NTN, NTT, CXC3, CXC3C, SCYD1, ABCD-3, C3Xkine, fractalkine, neurotactin, FKN, A-152E5.2, Fractalkine, C-X3-C motif chemokine 1
Application Note:
CX3CL1 antibody can be used for detection of CX3CL1 by Western blot at 0.5 - 2 μg/mL dilution. CX3CL1 is ofen observed migrating at 80 - 100 kDa in SDS-PAGE, presumably due to post-translational modification.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.
Background:
CX3CL1 Antibody: Chemokines are a family of proteins associated with the trafficking of leukocytes in immune surveillance and inflammatory cell recruitment. They are classified based on the positions of key cysteine residues. CX3CL1 is a CX3C chemokine known to induce adhesion and migration of leukocytes mediated by a membrane-bound and soluble form respectively. Recent experiments have shown that CX3CL1 can suppress the production of nitrous oxide, interleukin-6, and TNF-α in activated microglia and neuronal cells, suggesting that it may act as an intrinsic inhibitor against neurotoxicity by activated microglia. Its receptor, CX3CR1, also functions as a co-receptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by CX3CL1.
Background References:
- Bajetto A, Bonavia R, Barbero S, et al. Chemokines and their receptors in the central nervous system. Front. Neuroendocrinol. 2001; 22:147-84.
- Umehara H, Goda S, Imai T, et al. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol. Cell. Biol. 2001; 79:298-302.
- Mizuno T, Kawanokuchi J, Numata K, et al. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003; 979:65-70.
- Combadiere C, Salzwedel K, Smith ED, et al. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J. Biol. Chem.1998; 273:23799-804.
Buffer:
CX3CL1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (79%)
Immunogen:
CX3CL1 antibody was raised against a peptide corresponding to 18 amino acids near the amino terminus of human CX3CL1.
The immunogen is located within amino acids 20 - 70 of CX3CL1.
The immunogen is located within amino acids 20 - 70 of CX3CL1.
NCBI Gene ID #:
6376
NCBI Official Name:
chemokine (C-X3-C motif) ligand 1
NCBI Official Symbol:
CX3CL1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAB50014
Protein GI Number:
1899259
Purification:
CX3CL1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,Innate Immunity,Chemokines & Cytokines
Swissprot #:
P78423
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | CX3CL1 Peptide | PSI-2099P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|